Please use this identifier to cite or link to this item:
https://doi.org/10.3390/cells11060941
DC Field | Value | |
---|---|---|
dc.title | Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma | |
dc.contributor.author | Zhou, Jianbiao | |
dc.contributor.author | Chng, Wee-Joo | |
dc.date.accessioned | 2022-07-21T04:32:07Z | |
dc.date.available | 2022-07-21T04:32:07Z | |
dc.date.issued | 2022-03-01 | |
dc.identifier.citation | Zhou, Jianbiao, Chng, Wee-Joo (2022-03-01). Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma. CELLS 11 (6). ScholarBank@NUS Repository. https://doi.org/10.3390/cells11060941 | |
dc.identifier.issn | 2073-4409,2073-4409 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/228991 | |
dc.description.abstract | Multiple myeloma (MM) is the second most common hematological malignancy, characterized by an abnormal accumulation of plasma cells in the bone marrow. Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that modulates the transcription of multiple genes to regulate various principal biological functions, for example, cell proliferation and survival, stemness, inflammation and immune responses. Aberrant STAT3 activation has been identified as a key driver of tumorigenesis in many types of cancers, including MM. Herein, we summarize the current evidence for the role of STAT3 in affecting cancer hallmark traits by: (1) sustaining MM cell survival and proliferation, (2) regulating tumor microenvironment, (3) inducing immunosuppression. We also provide an update of different strategies for targeting STAT3 in MM with special emphasis on JAK inhibitors that are currently undergoing clinical trials. Finally, we discuss the challenges and future direction of understanding STAT3 signaling in MM biology and the clinical development of STAT3 inhibitors. | |
dc.language.iso | en | |
dc.publisher | MDPI | |
dc.source | Elements | |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Cell Biology | |
dc.subject | multiple myeloma | |
dc.subject | signal transducer and activator of transcription 3 (STAT3) | |
dc.subject | hallmarks of cancer | |
dc.subject | targeted therapy | |
dc.subject | JAK inhibitor | |
dc.subject | BONE-MARROW MICROENVIRONMENT | |
dc.subject | SUPER-ANTAGONIST SANT7 | |
dc.subject | KINASE INHIBITOR | |
dc.subject | DENDRITIC CELLS | |
dc.subject | TRANSCRIPTION 3 | |
dc.subject | PHASE-I | |
dc.subject | APOPTOSIS | |
dc.subject | PRL-3 | |
dc.subject | COMBINATION | |
dc.subject | PHOSPHATASE | |
dc.type | Review | |
dc.date.updated | 2022-07-17T12:03:41Z | |
dc.contributor.department | DEAN'S OFFICE (MEDICINE) | |
dc.contributor.department | PAEDIATRICS | |
dc.description.doi | 10.3390/cells11060941 | |
dc.description.sourcetitle | CELLS | |
dc.description.volume | 11 | |
dc.description.issue | 6 | |
dc.published.state | Published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma. .pdf | Published version | 611.92 kB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.